GX1.F Marker Therapeutics, Inc.
- Market cap
- EUR 11.8M
- P/E
- -
- P/B
- 1.23x
- ROE
- -82.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GX1.F undervalued?
Graham numberThe Graham number of Marker Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Marker Therapeutics, Inc. fundamental analysis
No fundamental analysis for Marker Therapeutics, Inc. yet.
Marker Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601…
Full company profileMarker Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Marker Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 3.31M | 0.00 | 0.00 | 0.00 |
| Operating Income | -39.5M | -19.8M | -11.3M | -11.1M | -12.4M | -10.5M |
| EBITDA | - | -19.8M | -11.3M | -11.1M | -12.4M | -10.5M |
| Net Income | -41.9M | -29.9M | -8.24M | -10.7M | -12.2M | -10.0M |
| EPS | -5.04 | -3.56 | -0.93 | -1.00 | -0.73 | -0.60 |
| Balance Sheet | ||||||
| Total Assets | 68.1M | 34.4M | 17.1M | 22.0M | 19.1M | 14.6M |
| Total Liabilities | 24.1M | 14.8M | 3.07M | 3.46M | 2.27M | 2.42M |
| Shareholders' Equity | 44.0M | 19.6M | 14.1M | 18.6M | 16.8M | 12.2M |
| Cash & Short-term Investments | 42.4M | 11.8M | 15.1M | 19.2M | 16.1M | 11.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -27.3M | -27.0M | -16.4M | -10.9M | -12.0M | -10.2M |
| Capital Expenditure | 3.13M | 4.95M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -30.4M | -27.0M | -16.4M | -10.9M | -12.0M | -10.2M |
| Ratios | ||||||
| ROE | -95.2% | -152.7% | -58.6% | -57.8% | -72.4% | -82.3% |
| ROA | -61.5% | -87.0% | -48.1% | -48.7% | -63.8% | -68.6% |
| Net Profit Margin | - | - | -248.8% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Marker Therapeutics, Inc. dividends
Marker Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Jan 27, 2023.
Who owns Marker Therapeutics, Inc.
- Insiders 5.49%
- Institutions 23.54%
- Public & others 70.97%
- Shares outstanding 16.7M
- Free float 13.7M
Marker Therapeutics, Inc. company profile
- Company name
- Marker Therapeutics, Inc.
- Ticker
- GX1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 2450 Holcombe Blvd, Houston, TX, United States, 77021
- Phone
- 713 400 6400
- Website
- markertherapeutics.com
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Marker Therapeutics, Inc. management
7- Dr. Juan F. Vera M.D.Co-Founder, CEO, President, Treasurer, Secretary & Director · born 1980
- Ms. Elizabeth DonnellyDirector of Administration
- Dr. Maria-Bernadette Madel Ph.D.Director of Corporate Operations & External Communications · born 1990
- Mr. Edmund CheungVice President of Human Resources
- Patricia AllisonHead of Clinical Operations
- Ms. Mary Newman Ph.D.Head of Regulatory Affairs · born 1959
- Dr. Robert Z. Florkiewicz Sr., Ph.D.Senior Director of Molecular Biology & Virology